Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1544608

registered interest
date	22/11/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Rheumatoid Arthritis: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of rheumatoid arthritis patients received a biologic in the last 12 months.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	93514
answer	answer is ministerial correction date of answer 25/11/2022 answer text <p>This information is not collected in the format requested.</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately grouped question UIN 93513 question first answered 25/11/2022 12:58:14 answering member 4527 label Biography information for Helen Whately
tabling member	4034 label Biography information for Yvonne Fovargue

1491401

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lung Diseases: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he plans to amend the respiratory outcomes section in the update of the NHS Long Term Plan.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41993
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.</p><p>There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 41994 question first answered 05/09/2022 11:27:51 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1491402

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Asthma: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, If he will include metrics on the uptake of biologics for severe asthma in the update to the NHS Long Term Plan.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41994
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>The Department and NHS England are currently reviewing delivery of the commitments made in the NHS Long Term Plan, including those relating to respiratory outcomes. The update to the NHS Long Term Plan will be published later this year.</p><p>There are no current plans to include metrics measuring uptake of biologics in the NHS Long Term Plan update. However, pathways to biologic therapy are being streamlined, including through the Accelerated Access Collaborative’s work to improve the identification of patients in primary and secondary care settings for referrals to assess suitability to receive biologic treatment.</p> answering member constituency Chichester answering member printed Gillian Keegan grouped question UIN 41993 question first answered 05/09/2022 11:27:51 answering member 4680 label Biography information for Gillian Keegan
tabling member	4034 label Biography information for Yvonne Fovargue

1491423

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Obstructive Pulmonary Disease: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has plans to include incentives within the Quality and Outcomes Framework or Investment and Impact Fund to help ensure that chronic obstructive pulmonary disease (COPD) patients receive a proactive review of their care after a prescription of oral corticosteroid for a COPD exacerbation.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41995
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>We have no specific plans to do so. However, the Quality and Outcomes Framework and the Investment and Impact Fund are reviewed to ensure alignment with the latest clinical guidance and best practice.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 10:38:51 answering member 3992 label Biography information for James Morris
tabling member	4034 label Biography information for Yvonne Fovargue

1491425

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Obstructive Pulmonary Disease: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of patients who have received all components of the discharge bundle included in the Best Practice Tariff for chronic obstructive pulmonary disease in the last 12 months.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41996
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>No specific estimate has been made. Compliance with the Best Practice Tariff criteria is measured by the National COPD Audit Programme’s secondary care audit.</p><p> </p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 10:40:38 answering member 3992 label Biography information for James Morris
tabling member	4034 label Biography information for Yvonne Fovargue

1491427

registered interest
date	21/07/2022
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Chronic Obstructive Pulmonary Disease: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether he has plans to include measures to promote an increase in treatment reviews of chronic obstructive pulmonary disease patients who are risk of exacerbation within CORE20+5.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41997
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>There are no plans to do so. However, Core20PLUS5 supports increasing the uptake of COVID-19, flu and pneumonia vaccines to reduce infective exacerbations and potential emergency hospital admissions.</p> answering member constituency Halesowen and Rowley Regis answering member printed James Morris question first answered 05/09/2022 11:13:19 answering member 3992 label Biography information for James Morris
tabling member	4034 label Biography information for Yvonne Fovargue

1491429

registered interest
date	21/07/2022
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Fluorinated Gases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, whether his Department has conducted modelling on the impact of the potential removal of medical exemption to the F gas phase down schedule on the cost of medicines.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41998
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>Defra is reviewing the F-gas Regulation, which includes an exemption from the hydrofluorocarbon phasedown for metered dose inhalers (MDIs). The review will consider the implementation of the current F-gas Regulation and options for future policy development. The implications of removing the exemption for MDIs, including the potential impact of this on cost and supply, will be included in the analysis.</p><p> </p><p>NHS England is in the process of reducing the use of MDIs containing high global warming potential propellants and has produced cost estimates for the switch from MDIs to currently readily available alternatives. These cost estimates will be incorporated in Defra’s work.</p><p> </p><p>Defra is working on this review jointly with the Scottish and Welsh Governments and we plan to consult on proposed future policies next year.</p> answering member constituency St Austell and Newquay answering member printed Steve Double question first answered 05/09/2022 07:09:16 answering member 4452 label Biography information for Steve Double
tabling member	4034 label Biography information for Yvonne Fovargue

1491432

registered interest
date	21/07/2022
answering body	Department for Environment, Food and Rural Affairs
answering dept id	13
answering dept short name	Environment, Food and Rural Affairs
answering dept sort name	Environment, Food and Rural Affairs
hansard heading	Fluorinated Gases
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Environment, Food and Rural Affairs, if he will hold discussions with the Secretary of State for Health and Social Care on a timescale for the phasedown of the use of fluorinated gases in asthma inhalers.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	41999
answer	answer is ministerial correction date of answer 05/09/2022 answer text <p>Defra has a legal duty to undertake a comprehensive review of the F-gas Regulation. As part of this work, Defra will identify additional action that can be taken with regard to F-gases and their contribution to net zero. At COP26, Defra committed to an accelerated hydrofluorocarbon (HFC) phasedown. Defra intends to publish an assessment report by the end of 2022 as the first stage of the review. It will focus mainly on analysing the effects of the current Regulation, together with the current state of play in relevant industry sectors and international commitments. The second stage of the review will involve a public consultation on proposals for any legislative changes.</p><p>The F-gas Regulation currently includes an exemption from the HFC phasedown for metered dose inhalers (MDIs). The continuation or removal of the exemption for MDIs will be considered as part of the policy development and analysis into future options, as well as implications of the HFC phasedown on MDIs. To support this work there is ongoing engagement between Defra, the NHS and the Department of Health and Social Care.</p> answering member constituency St Austell and Newquay answering member printed Steve Double question first answered 05/09/2022 07:05:41 answering member 4452 label Biography information for Steve Double
tabling member	4034 label Biography information for Yvonne Fovargue

1487016

registered interest
date	06/07/2022
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Silica: Health and Safety
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, what steps she has taken to help reduce exposure to respirable crystalline silica in the workplace.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	31816
answer	answer is ministerial correction date of answer 12/07/2022 answer text <p>The Health and Safety Executive (HSE) has a well-established regulatory framework in place to protect workers from the health risks associated with exposure to hazardous substances at work.</p><p> </p><p>Under the <a href="https://www.legislation.gov.uk/uksi/2002/2677/introduction/made" target="_blank">Control of Substances Hazardous to Health Regulations 2002 (COSHH)</a> employers have a duty to prevent or adequately control worker exposure to hazardous substances such as Respirable Crystalline Silica (RCS). COSHH sets out the hierarchy of control that must be implemented and, if managed appropriately, should result in achieving a level below the Work Exposure Limit (WEL) as detailed in HSE Guidance ‘<a href="https://www.hse.gov.uk/pubns/books/eh40.htm" target="_blank">EH40/2005, Workplace exposure limits</a>’.</p><p><br> HSE also delivers communications campaigns to support its regulatory activity. These campaigns inform duty holders and workers of the hazards faced and how these should be controlled and monitored. HSE’s dust campaign which ran in late 2021, included silica exposure, and involved social media and press activity to support awareness of the risks and how to control them.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 12/07/2022 12:08:54 answering member 1609 label Biography information for Chloe Smith
tabling member	4034 label Biography information for Yvonne Fovargue

1487017

registered interest
date	06/07/2022
answering body	Department for Work and Pensions
answering dept id	29
answering dept short name	Work and Pensions
answering dept sort name	Work and Pensions
hansard heading	Silicosis
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Work and Pensions, whether she plans to make silicosis a notifiable disease under the Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013.
tabling member constituency	Makerfield
tabling member printed	Yvonne Fovargue
uin	31817
answer	answer is ministerial correction date of answer 12/07/2022 answer text <p>The Reporting of Injuries, Diseases and Dangerous Occurrences Regulations 2013 (RIDDOR) are made under the Health and Safety at Work etc. Act 1974 and apply to all sectors and workplaces in Great Britain.</p><p> </p><p>The 2013 regulations clarified and simplified the list of reportable ill-health conditions (occupational diseases), as a result of a recommendation made by Professor Löfstedt in his report “<a href="https://www.gov.uk/government/publications/reclaiming-health-and-safety-for-all-lofstedt-report" target="_blank">Reclaiming health and safety for all: An independent review of health and safety legislation</a>,” published in 2011.</p><p> </p><p>The Health and Safety Executive (HSE) keeps the regulations, including specified injuries and reportable diseases, under review. The list of current reportable occupational diseases, including silicosis, will be considered as part of the next formal post-implementation review of RIDDOR, which is due to report in October 2023. HSE will engage with a range of stakeholders as part of the review process.</p> answering member constituency Norwich North answering member printed Chloe Smith question first answered 12/07/2022 12:05:42 answering member 1609 label Biography information for Chloe Smith
tabling member	4034 label Biography information for Yvonne Fovargue